Freehold, NJ, Aug. 23, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and Specialty Pharmacy Drug Consulting Services, is pleased to announce an update for its laser division.
Medifirst is pleased to announce that they have been working with the Antah HealthCare Group and Fullerton Health to introduce the Time Machine Laser as a drug-free and natural treatment for pain and inflammation. Antah HealthCare Group is one of the largest Malaysian owned healthcare marketing and distribution companies in Malaysia. They have over 250 employees with branch offices located at major cities nationwide. The group has over 50 years of experience in the healthcare industry. Additionally, Fullerton Health is in the process of testing the Time Machine Laser at its Singapore facilities. Fullerton Health is a leading vertically integrated healthcare platform in the Asia Pacific region. Founded in Singapore in 2011, they own and operate an extensive network of healthcare facilities across 8 countries and partner with established and reputable healthcare providers in the region. As a pioneer of healthcare innovation, they leverage technology to provide cost-effective management and administration of healthcare services. Commented Medifirst President, Bruce J. Schoengood, “We are very pleased and excited to be working with such established healthcare leaders and introduce our laser to the Asia Pacific market. Both companies are committed to seeking drug free and natural pain solutions that effect tens of thousands of lives. Although definitive agreements have not been finalized, we are very optimistic about our progress and the enthusiasm of these healthcare companies with regards to our laser. We anticipate further announcements in the upcoming days and weeks.”
NAALT 2018 CONFERENCE North American Association for Photobiomodulation Therapy This past week, our V.P. and Medical Director, Dr. Ronald Rubin was invited and honored to speak and introduce The Time Machine Laser at this prestigious conference. The NAALT 2018 conference focus was Photobiomodulation and Drug-Free Management of Pain with the emphasis on treatment of pain and the acceleration of tissue healing.
As been widely reported, President Trump has declared a State of Opioid Emergency. A public health emergency exists, and it is our belief, that laser technology can provide a viable pain treatment solution that is drug-free. The purpose of NAALT is to be a forum for therapeutic light therapy practitioners in North America (Mexico, USA and Canada), as well as many other countries that attended the conference. Its goal is to promote phototherapy as a valid treatment, and to improve understanding of photobiological mechanisms, basic therapeutic light physics, safety, treatment parameters, techniques, regulatory issues and reimbursement. Panels of researchers and clinicians from around the world gathered together to share their research and clinical experience in the effective drug-free management of pain.
Commented Dr. Rubin, “This was an amazing opportunity to introduce our Time Machine Laser device to such leading and esteemed experts including Dr. Michael Hamblin, of the Wellman Center for Photomedicine, a teaching Affiliate of the Harvard Medical School. Dr. Hamblin is widely recognized as the leading expert in low light laser therapy and photobiomodulation. I was delighted to meet colleagues from around the world and I am confident that this conference will lead to many new opportunities for Medifirst and the Time Machine Laser.”
About CCRx CCRx services of specialty drug pharmacy consulting and revenue stream management utilizes over 60 years of combined specialty pharmacy and infusion therapy experience. The services are designed to increase profits for pharmacies. Services include: clinical review, expedited medical insurance verification, training for drug dispensing, insurance billing, collections, and reconciliation. The billing services will address any denials and include appeals and resubmissions. The division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding market of the specialty pharmacy market in today's healthcare system.
Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, are costly, and require ongoing clinical support, we believe, will drive nearly all the pharmaceutical industry’s market growth from 2015–2020. Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue. If these projections hold true, specialty drugs will have increased their revenues by over 5X from 2010–2020, growing from just 15% of the market to nearly half in that decade.
About The Time Machine Laser Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
Forward-Looking Statements: The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Investor Relations Phone: (732) 786-8044 Email: admin@medifirstsolutions.com Website: www.medifirstsolutions.com
